Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Novo Nordisk preps filings for sickle cell drug etavopivat

 April 21, 2026

Pharmaphorum

Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.

RegulatoryHematologyRead full story

Post navigation

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data →
← Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com